Trial Profile
Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Gadovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary)
- Indications Vascular disorders
- Focus Adverse reactions
- Acronyms GRIP
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 15 Feb 2017 New trial record
- 01 Jan 2017 Results published in the Investigative Radiology.